Dongwei Zhang

Dr. Dongwei Zhang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2020 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
XLXiaoyan Liao
Xiaoyan Liao
XLXiuli Liu
Xiuli Liu
XFXuemo Fan
Xuemo Fan
JLJinping Lai
Jinping Lai
DZDongwei Zhang
Dongwei Zhang
Background: Perianal Paget’s disease (PPD) is rare and mostly described in clinical literature as case reports or small series. Methods: We investigated the clinicopathologic and immunohistochemical features of PPD in a total of 13 cases retrieved from multiple academic institutions. Results: The median age at diagnosis was 75 (range 50–86) years. Males were predominant with a male to female ratio of 2.25:1. Four (30.8%) cases were classified as primary PPD due to lack of synchronous or metachronous underlying malignancies, while nine (69.2%) were classified as secondary PPD with concurrent invasive adenocarcinoma (n = 8) or tubular adenoma with high-grade dysplasia (n = 1). Immunohistochemically, there is no differential expression of CK7 or CK20 in Paget’s cells between primary and secondary PPD; however, GCDFP-15 was only positive in primary PPD (3/3 vs. 0/6, P = 0.012), while CDX2 was only positive in secondary PPD (0/3 vs. 7/7, P = 0.008), suggesting different cell origin. All patients received local surgical resection with or without adjuvant therapy. After a median follow-up of 47 months, one patient with secondary PPD (7.7%) died of disease progression from underlying adenocarcinoma. Conclusions: PPD occurs in elderly patients with male predominance and is frequently associated with underlying malignancies. Differential expression of CDX2 and GCDFP-15 may help distinguishing primary vs. secondary PPD, which is important for management as the presence of an underlying malignancy impacts clinical course and prognosis. Surgical excision remains the major treatment strategy for PPD. Long-term follow-up is required to monitor the disease recurrence and metastasis.

15 November 2019 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
DZDongwei Zhang
Dongwei Zhang
RGRaul S. Gonzalez
Raul S. Gonzalez
MFMichael Feely
Michael Feely
KUKavita Umrau
Kavita Umrau
HLHwajeong Lee
Hwajeong Lee
XLXiuli Liu
Xiuli Liu

9 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
HLHuijie Liu
Huijie Liu
ADAyse Ece Cali Daylan
Ayse Ece Cali Daylan
JYJihua Yang
Jihua Yang
ATAnkit Tanwar
Ankit Tanwar
ABAlain Borczuk
Alain Borczuk
HCHaiying Cheng
Haiying Cheng
Despite major advances in non-small-cell lung cancer (NSCLC) treatment, the five-year survival rates for patients with non-oncogene-driven tumors remain low, necessitating combinatory approaches to improve outcomes. Our prior high-throughput RNAi screening identified Aurora kinase A (AURKA) as a potential key player in cisplatin resistance. In this study, we investigated AURKA’s role in platinum and radiation sensitivity in multiple NSCLC cell lines and xenograft mouse models, as well as its effect on immune checkpoints, including PD-L1, B7x, B7-H3, and HHLA2. Of 94 NSCLC patient tumor specimens, 91.5% tested positive for AURKA expression, with 34% showing moderate-to-high levels. AURKA expression was upregulated following cisplatin treatment in NSCLC cell lines PC9 and A549. Both AURKA inhibition by alisertib and inducible AURKA knockdown potentiated the cytotoxic effects of cisplatin and radiation, leading to tumor regression in doxycycline-inducible xenograft mice. Co-treated cells exhibited increased DNA double-strand breaks, apoptosis, and senescence. Additionally, AURKA inhibition alone by alisertib increased PD-L1 and B7-H3 expression. In conclusion, our study demonstrates that AURKA inhibition enhances the efficacy of platinum-based chemotherapy in NSCLC cells and modulates the expression of multiple immune checkpoints. Therefore, combinatory regimens with AURKA inhibitors should be strategically designed and further studied within the evolving landscape of chemo-immunotherapy.

1 December 2020 in Human Pathology
Verified
Journal Article
Closed access
PLPhilippa Li
Philippa Li
DZDongwei Zhang
Dongwei Zhang
JZJiehao Zhou
Jiehao Zhou
PLPeng Li
Peng Li
YSYulei Shen
Yulei Shen
XLXiaoyan Liao
Xiaoyan Liao

24 December 2020 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
PDF file
RKRoula Katerji
Roula Katerji
XLXiaoyan Liao
Xiaoyan Liao
AHAaron Huber
Aaron Huber
DZDongwei Zhang
Dongwei Zhang
Primary adenocarcinoma of the anorectum, compared with squamous cell carcinoma, is a rarer and more aggressive malignant neoplasm. Infection with human papillomavirus (HPV) has been identified as a causal agent in a variety of tumors, including those of the cervix, head and neck, and anogenital region, especially squamous cell carcinoma. However, the relationship between HPV and anorectal adenocarcinoma has not been well studied. In this article, we report an HPV-related anorectal adenocarcinoma arising in a tubulovillous adenoma in a 76 years old female who presented initially with lower gastrointestinal bleeding. The carcinoma cells were positive for cytokeratin 7 and p16 by immunohistochemistry. High-risk HPV RNA in situ hybridization was positive. A follow-up examination of the anal area showed perianal plaques. Histologically, the excision of the perianal lesion showed intraepithelial infiltration by sheets and clusters of large atypical neoplastic cells. The neoplastic cells showed the same immunoprofile compared with the anorectal adenocarcinoma with p16 and high-risk HPV positivity. The findings are consistent with extramammary perianal Paget’s disease secondary to anorectal adenocarcinoma. HPV-related adenocarcinoma in the anorectum is a newly recognized entity and was previously considered clinically indolent. Our case uniquely exhibits adenoma-carcinoma-perianal Paget’s disease sequence, which has not been reported before. Our findings suggest that evaluation of the patient’s lower genital tract for any HPV-associated lesions and long-term follow-up are required to monitor the disease progression in this type of malignancy.

29 December 2020 in Hepatic Oncology
Verified
Journal Article
Open access
NNNumbereye Numbere
Numbereye Numbere
DZDongwei Zhang
Dongwei Zhang
DADiana Agostini-Vulaj
Diana Agostini-Vulaj
Worldwide, primary liver cancer is the fourth leading cause of cancer mortality. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Sarcomatoid hepatocellular carcinoma...